Pharmacogenomic analyses of sunitinib in patients with
pancreatic neuroendocrine tumors

J 2019

Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors

FAZIO, Nicola; Jean-Francois MARTINI; Adina E. CROITORU; Michael SCHENKER; Sherry LI et. al.

Základní údaje

Originální název

Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors

Autoři

FAZIO, Nicola (380 Itálie); Jean-Francois MARTINI (840 Spojené státy); Adina E. CROITORU (642 Rumunsko); Michael SCHENKER (642 Rumunsko); Sherry LI (840 Spojené státy); Brad ROSBROOK (840 Spojené státy); Kathrine FERNANDEZ (840 Spojené státy); Jiří TOMÁŠEK (203 Česká republika, domácí); Espen THIIS-EVENSEN (578 Norsko); Matthew KULKE (840 Spojené státy) a Eric RAYMOND (250 Francie)

Vydání

Future Oncology, London, Future Medicine Ltd. 2019, 1479-6694

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.660

Kód RIV

RIV/00216224:14110/19:00112848

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.2217/fon-2018-0934

UT WoS

000474879700006

EID Scopus

2-s2.0-85068570739

Klíčová slova anglicky

biomarkers; efficacy; pancreatic neuroendocrine tumor; sunitinib; VEGF

Štítky

14110811, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 3. 2020 14:22, Mgr. Tereza Miškechová

Anotace

V originále

Aim: Evaluate associations between clinical outcomes and SNPs in patients with well-differentiated pancreatic neuroendocrine tumors receiving sunitinib. Patients & methods: Kaplan-Meier and Cox proportional hazards models were used to analyze the association between SNPs and survival outcomes using data from a sunitinib Phase IV (genotyped, n = 56) study. Fisher's exact test was used to analyze objective response rate and genotype associations. Results: After multiplicity adjustment, progression-free and overall survivals were not significantly correlated with SNPs; however, a higher objective response rate was significantly associated with IL1B rs16944 G/A versus G/G (46.4 vs 4.5%; p = 0.001). Conclusion: IL1B SNPs may predict treatment response in patients with pancreatic neuroendocrine tumors. VEGF pathway SNPs are potentially associated with survival outcomes.

Citovat

FAZIO, Nicola; Jean-Francois MARTINI; Adina E. CROITORU; Michael SCHENKER; Sherry LI; Brad ROSBROOK; Kathrine FERNANDEZ; Jiří TOMÁŠEK; Espen THIIS-EVENSEN; Matthew KULKE a Eric RAYMOND. Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors. Future Oncology. London: Future Medicine Ltd., 2019, roč. 15, č. 17, s. 1997-2007. ISSN 1479-6694. Dostupné z: https://doi.org/10.2217/fon-2018-0934.

@article{1615257,
   author = {Fazio, Nicola and Martini, JeanandFrancois and Croitoru, Adina E. and Schenker, Michael and Li, Sherry and Rosbrook, Brad and Fernandez, Kathrine and Tomášek, Jiří and ThiisandEvensen, Espen and Kulke, Matthew and Raymond, Eric},
   article_location = {London},
   article_number = {17},
   doi = {https://doi.org/10.2217/fon-2018-0934},
   keywords = {biomarkers; efficacy; pancreatic neuroendocrine tumor; sunitinib; VEGF},
   language = {eng},
   issn = {1479-6694},
   journal = {Future Oncology},
   title = {Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors},
   url = {http://dx.doi.org/10.2217/fon-2018-0934},
   volume = {15},
   year = {2019}
}

TY  - JOUR
ID  - 1615257
AU  - Fazio, Nicola - Martini, Jean-Francois - Croitoru, Adina E. - Schenker, Michael - Li, Sherry - Rosbrook, Brad - Fernandez, Kathrine - Tomášek, Jiří - Thiis-Evensen, Espen - Kulke, Matthew - Raymond, Eric
PY  - 2019
TI  - Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors
JF  - Future Oncology
VL  - 15
IS  - 17
SP  - 1997-2007
EP  - 1997-2007
PB  - Future Medicine Ltd.
SN  - 14796694
KW  - biomarkers
KW  - efficacy
KW  - pancreatic neuroendocrine tumor
KW  - sunitinib
KW  - VEGF
UR  - http://dx.doi.org/10.2217/fon-2018-0934
L2  - http://dx.doi.org/10.2217/fon-2018-0934
N2  - Aim: Evaluate associations between clinical outcomes and SNPs in patients with well-differentiated pancreatic neuroendocrine tumors receiving sunitinib. Patients & methods: Kaplan-Meier and Cox proportional hazards models were used to analyze the association between SNPs and survival outcomes using data from a sunitinib Phase IV (genotyped, n = 56) study. Fisher's exact test was used to analyze objective response rate and genotype associations. Results: After multiplicity adjustment, progression-free and overall survivals were not significantly correlated with SNPs; however, a higher objective response rate was significantly associated with IL1B rs16944 G/A versus G/G (46.4 vs 4.5%; p = 0.001). Conclusion: IL1B SNPs may predict treatment response in patients with pancreatic neuroendocrine tumors. VEGF pathway SNPs are potentially associated with survival outcomes.
ER  -

FAZIO, Nicola; Jean-Francois MARTINI; Adina E. CROITORU; Michael SCHENKER; Sherry LI; Brad ROSBROOK; Kathrine FERNANDEZ; Jiří TOMÁŠEK; Espen THIIS-EVENSEN; Matthew KULKE a Eric RAYMOND. Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors. \textit{Future Oncology}. London: Future Medicine Ltd., 2019, roč.~15, č.~17, s.~1997-2007. ISSN~1479-6694. Dostupné z: https://doi.org/10.2217/fon-2018-0934.

Přehled o publikaci